Pachastrissamine (jaspine B) and its stereoisomers inhibit sphingosine kinases and atypical protein kinase C

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 18, 2011, Pages 5402-5408

  Yoshimitsu, Yuji ^a   Oishi, Shinya ^a   Miyagaki, Jun ^a   Inuki, Shinsuke ^a   Ohno, Hiroaki ^a   Fujii, Nobutaka ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Jaspine B; Pachastrissamine; Protein kinase C; Sphingolipid; Sphingosine kinase

Indexed keywords

1 [2 OXO 4 [(TRIISOPROPYLSILYLOXY)METHYL]OXAZOLIDIN 5 YL]PENTADECYL ACETATE; 2 [(TERT BUTOXYCARBONYL)AMINO] 1 (TRIISOPROPYLSILYLOXY)OCTADECANE 3,4 DIYL BIS(METHYLBENZENESULFONATE); 4 [(TERT BUTOXYCARBONYL)AMINO] 2 TETRADECYLTETRAHYDROFURAN 3 YL 4 METHYLBENZENESULFONATE; 4 AMINO 2 TETRADECYLTETRAHYDROFURAN 3 OL; 4 AMINO 2 TETRADECYLTETRAHYDROFURAN 3 YL 4 METHYLBENZENESULFONATE; N,N DIMETHYLSPHINGOSINE; PACHASTRISSAMINE; PROTEIN KINASE C IOTA; PROTEIN KINASE C ZETA; SPHINGOSINE DERIVATIVE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; TERT BUTYL 4 (HEXADEC 1 EN 1 YL) 2,2 DIMETHYLOXAZOLIDINE 3 CARBOXYLATE; TERT BUTYL 4 [1,2 BIS(TOSYLOXY)HEXADECYL] 2,2 DIMETHYLOXAZOLIDINE 3 CARBOXYLATE; TERT BUTYL 4 [1,2 DIHYDROXYHEXADECYL] 2,2 DIMETHYLOXAZOLIDINE 3 CARBOXYLATE; TERT BUTYL [1,3,4 TRIHYDROXYOCTADECAN 2 YL]CARBAMATE; TERT BUTYL [3,4 DIHYDROXY 1 (TRIISOPROPYLSILYLOXY)OCTADECAN 2 YL]CARBAMATE; TERT BUTYL [4 HYDROXY 5 TETRADECYLTETRAHYDROFURAN 3 YL]CARBAMATE; TERT BUTYL [4 HYDROXY 5 TRIHYDROXYOCTADECAN 3 YL]CARBAMATE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; STEREOISOMERISM;

DOSE-RESPONSE RELATIONSHIP, DRUG; MOLECULAR CONFORMATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SPHINGOSINE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860390250     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.07.061     Document Type: Article

References (35)

1. For a review, see: H. Fyrst, and J.D. Saba Nat. Chem. Biol. 6 2010 489
2. Y.A. Hannun J. Biol. Chem. 269 1994 3125
3. S. Spiegel, and S. Milstien J. Biol. Chem. 277 2002 25851
4. K. Takabe, S.W. Paugh, S. Milstien, and S. Spiegel Pharmacol. Rev. 60 2008 181
5. N.J. Pyne, and S. Pyne Nat. Rev. Cancer 10 2010 489
6. T. Kohama, A. Olivera, L. Edsall, M.M. Negiec, R. Dickson, and S. Spiegel J. Biol. Chem. 273 1998 23722
7. H. Liu, M. Sugiura, V.E. Nava, L.C. Edsall, K. Kono, S. Poulton, S. Milstien, T. Kohama, and S. Spiegel J. Biol. Chem. 275 2000 19513
8. P. Xia, J.R. Gamble, L. Wang, S.M. Pitson, P.A. Moretti, B.W. Wattenberg, R.J. D'Andrea, and M.A. Vadas Curr. Biol. 10 2000 1527
9. D. Pchejetski, M. Golzio, E. Bonhoure, C. Calvet, N. Doumerc, V. Garcia, C. Mazerolles, P. Rischmann, J. Teissié, B. Malavaud, and O. Cuvillier Cancer Res. 65 2005 11667
10. L. Sauer, J. Nunes, V. Salunkhe, L. Skalska, T. Kohama, O. Cuvillier, J. Waxman, and D. Pchejetski Int. J. Cancer 125 2009 2728
11. H. Liu, R.E. Toman, S.K. Goparaju, M. Maceyka, V.E. Nava, H. Sankala, S.G. Payne, M. Bektas, I. Ishii, J. Chun, S. Milstien, and S. Spiegel J. Biol. Chem. 278 2003 40330
12. L.R. Fitzpatrick, C. Green, L.W. Maines, and C.D. Smith Pharmacology 87 2011 135
13. For a review, see: M.R. Pitman, and S.M. Pitson Curr. Cancer Drug Targets 10 2010 354
14. I. Kuroda, M. Musman, I. Ohtani, T. Ichiba, J. Tanaka, D. Garcia-Gravalos, and T. Higa J. Nat. Prod. 65 2002 1505
15. D. Canals, D. Mormeneo, G. Fabris, A. Llebaria, J. Casas, and A. Delgado Bioorg. Med. Chem. 17 2009 235
16. G. Jayachitra, N. Sudhakar, R.K. Anchoori, V. Rao, S. Roy, and R. Banerjee Synthesis 2010 115
17. Y. Salma, E. Lafont, N. Therville, S. Carpentier, M.J. Bonnafe, T. Levade, Y. Génisson, and N. Andrieu-Abadie Biochem. Pharmacol. 78 2009 477
18. Y. Yoshimitsu, S. Inuki, S. Oishi, N. Fujii, and H. Ohno J. Org. Chem. 75 2010 3843
19. H. Azuma, S. Tamagaki, and K. Ogino J. Org. Chem. 65 2000 3538
20. R. van den Berg, T. Boltje, C. Verhagen, R. Litjens, G. Vander Marel, and H. Overkleeft J. Org. Chem. 71 2006 836
21. D. Perrin, C. Frémaux, and A. Scheer J. Biomol. Screen. 11 2006 359
22. Y. Yatomi, F. Ruan, T. Megidish, T. Toyokuni, S. Hakomori, and Y. Igarashi Biochemistry 35 1996 626
23. B.M. Buehrer, and R.M. Bell J. Biol. Chem. 267 1992 3154
24. Recently, anticancer activity of a series of 1-deoxysphingolipid stereoisomers was reported, see: A.M. Dougherty, F.E. McDonald, D.C. Liotta, S.J. Moody, D.C. Pallas, C.D. Pack, and A.H. Merrill Org. Lett. 8 2006 649
25. E.C. Garnier-Amblard, S.G. Mays, R.F. Arrendale, M.T. Baillie, A.S. Bushnev, D.G. Culver, T.J. Evers, J.J. Holt, R.B. Howard, L.S. Liebeskind, D.S. Menaldino, M.G. Natchus, J.A. Petros, H. Ramaraju, G.P. Reddy, and D.C. Liotta ACS Med. Chem. Lett. 2 2011 438
26. L. Wong, S.S.L. Tan, Y. Lam, and A.J. Melendez J. Med. Chem. 52 2009 3618
27. K. Kono, M. Tanaka, T. Ogita, and T. Kohama J. Antibiot. 53 2000 759
28. W.A. Khan, R. Dobrowsky, S.E. Touny, and Y.A. Hannun Biochem. Biophys. Res. Commun. 172 1990 683
29. S. Kimura, S. Kawa, F. Ruan, M. Nisar, Y. Sadahira, S. Hakomori, and Y. Igarashi Biochem. Pharmacol. 44 1992 1585
30. For a review, see: C. Rosse, M. Linch, S. Kermorgant, A.J.M. Cameron, K. Boeckeler, and P.J. Parker Nat. Rev. Mol. Cell Biol. 11 2010 103
31. A.P. Fields, and R.P. Regala Pharmacol. Res. 55 2007 487
32. K. Irie, K. Oie, A. Nakahara, Y. Yanai, H. Ohigashi, P.A. Wender, H. Fukuda, H. Konishi, and U. Kikkawa J. Am. Chem. Soc. 120 1998 9159
33. T.P. Mathews, A.J. Kennedy, Y. Kharel, P.C. Kennedy, O. Nicoara, M. Sunkara, A.J. Morris, B.R. Wamhoff, K.R. Lynch, and T.L. Macdonald J. Med. Chem. 53 2010 2766
34. W.J. van Blitterswijk Biochem. J. 331 1998 677
35. Although we assumed that pachastrissamines could mimic the structure of Cer, the potential inhibition of atypical PKCs by binding to the catalytic domain cannot be ruled out.